Results 21 to 30 of about 12,531 (249)
Frontiers in Cardiovascular Medicine, 2022 BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest.
Yu-Wen Chen +10 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 ObjectiveAcute heart failure (AHF) is associated with high mortality. Levosimendan, an inodilator, has proved to increase cardiac output and exert renoprotective effect in AHF.
Han Zhang +7 more
doaj +1 more source
Critical Care, 2020 Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock.
Enrique Guilherme +5 more
doaj +1 more source
Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery. a systematic review and meta-analysis [PDF]
, 2017 Background: Previous studies have shown beneficial effects of levosimendan in high-risk patients undergoing cardiac surgery. Two large randomized controlled trials (RCTs), however, showed no advantages of levosimendan.
Arcadipane, Antonio +8 more
core +2 more sources
BMC Anesthesiology, 2011 Background Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room.
Suominen Pertti K
doaj +1 more source
Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. [PDF]
Clin CardiolThe CYP3A5 rs776746 CC genotype is a strong biomarker for ticagrelor‐induced dyspnea, conferring a 2.3‐fold higher risk. Genotype‐guided antiplatelet therapy may mitigate this adverse reaction, enabling personalized treatment for ACS patients. ABSTRACT Background Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor is standard for patients with
Zhang Y +5 more
europepmc +2 more sources
PLoS ONE, 2020 INTRODUCTION:Levosimendan is approved for acute heart failure. Within this context, pulmonary hypertension represents a frequent co-morbidity. Hence, the effects of levosimendan on segmental pulmonary vascular resistance (PVR) are relevant.
Annette Dorothea Rieg +12 more
doaj +1 more source
What role does the right side of the heart play in circulation? [PDF]
, 2006 Right ventricular failure (RVF) is an underestimated problem in intensive care. This review explores the physiology and pathophysiology of right ventricular function and the pulmonary circulation.
Cecconi, M, Johnston, E, Rhodes, A
core +2 more sources
Oral Levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial [PDF]
, 2019 Objective To evaluate the efficacy and safety of oral levosimendan in amyotrophic lateral sclerosis (ALS) patients. This phase 2, randomised, double-blind, placebo-controlled, crossover, 3-period study with 6 months open-label follow-up enrolled adults ...
Aho, Valtteri V +8 more
core +2 more sources
Comparison of Levosimendan, Milrinone and Dobutamine in treating Low Cardiac Output Syndrome Following Valve Replacement Surgeries with Cardiopulmonary Bypass [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Low Cardiac Output Syndrome (LCOS) following Cardiopulmonary Bypass (CPB) is common and associated with increased mortality. Maintenance of adequate cardiac output is one of the primary objectives in management of such patients. Aim: To
Sunny +5 more
doaj +1 more source